Novacyt - Asset Resilience Ratio
Novacyt (ALNOV) has an Asset Resilience Ratio of 0.02% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Novacyt's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Novacyt's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Novacyt's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Novacyt's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Novacyt long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €9.99K | 0.02% |
| Total Liquid Assets | €9.99K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Novacyt maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novacyt Industry Peers by Asset Resilience Ratio
Compare Novacyt's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.29% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
DRTECH Corporation
KQ:214680 |
Medical Devices | 5.18% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
|
Implanet SA
PA:ALIMP |
Medical Devices | 0.55% |
Annual Asset Resilience Ratio for Novacyt (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Novacyt.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | €9.99K ≈ $11.68K |
€40.28 Million ≈ $47.09 Million |
-43.10pp |
| 2024-12-31 | 43.13% | €30.46 Million ≈ $35.61 Million |
€70.63 Million ≈ $82.58 Million |
+43.12pp |
| 2023-12-31 | 0.01% | €9.00K ≈ $10.52K |
€133.81 Million ≈ $156.44 Million |
-61.73pp |
| 2022-12-31 | 61.73% | €86.98 Million ≈ $101.69 Million |
€140.90 Million ≈ $164.73 Million |
+6.34pp |
| 2021-12-31 | 55.39% | €101.75 Million ≈ $118.96 Million |
€183.70 Million ≈ $214.76 Million |
+16.22pp |
| 2020-12-31 | 39.17% | €91.77 Million ≈ $107.29 Million |
€234.28 Million ≈ $273.89 Million |
+33.33pp |
| 2019-12-31 | 5.84% | €1.55 Million ≈ $1.81 Million |
€26.54 Million ≈ $31.03 Million |
+2.33pp |
| 2018-12-31 | 3.51% | €1.03 Million ≈ $1.20 Million |
€29.31 Million ≈ $34.27 Million |
+3.48pp |
| 2017-12-31 | 0.03% | €10.00K ≈ $11.69K |
€30.20 Million ≈ $35.31 Million |
+0.00pp |
| 2016-12-31 | 0.03% | €8.52K ≈ $9.97K |
€25.95 Million ≈ $30.34 Million |
-9.19pp |
| 2015-12-31 | 9.22% | €1.16 Million ≈ $1.36 Million |
€12.62 Million ≈ $14.76 Million |
+9.17pp |
| 2014-12-31 | 0.05% | €10.00K ≈ $11.69K |
€20.77 Million ≈ $24.28 Million |
-5.96pp |
| 2013-12-31 | 6.01% | €160.00K ≈ $187.06K |
€2.66 Million ≈ $3.11 Million |
-31.40pp |
| 2012-12-31 | 37.41% | €1.23 Million ≈ $1.44 Million |
€3.30 Million ≈ $3.86 Million |
+36.65pp |
| 2011-12-31 | 0.76% | €9.60K ≈ $11.22K |
€1.26 Million ≈ $1.47 Million |
+0.26pp |
| 2010-12-31 | 0.51% | €9.60K ≈ $11.22K |
€1.90 Million ≈ $2.22 Million |
-0.03pp |
| 2009-12-31 | 0.53% | €10.21K ≈ $11.94K |
€1.92 Million ≈ $2.24 Million |
-14.28pp |
| 2008-12-31 | 14.81% | €244.00K ≈ $285.26K |
€1.65 Million ≈ $1.93 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more